In stock
Fulphila injection
In stock
Only 1 left
SKU
10331014349
Fulphila injection (pegfilgrastim-cbqv) is a prescription medicine used to reduce the risk of infection, specifically febrile neutropenia, in cancer patients receiving myelosuppressive chemotherapy. It stimulates white blood cell production to help the body fight off infections. Administered as a single subcutaneous injection per chemotherapy cycle, it is a crucial therapy to support patients during their cancer treatment.
Fulphila injection is a biosimilar to Neulasta, approved to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Fulphila helps to stimulate the production of white blood cells, specifically neutrophils, which are crucial for fighting infections.
It significantly reduces the risk of febrile neutropenia, a severe complication of chemotherapy.
By preventing infections, Fulphila allows patients to continue their chemotherapy treatments with fewer interruptions.
It provides a convenient, single-dose option per chemotherapy cycle.
1. Fulphila is administered as a subcutaneous injection once per chemotherapy cycle.
2. The injection should be given at least 14 days before and 24 hours after a dose of myelosuppressive chemotherapy.
3. A healthcare professional will typically administer Fulphila.
4. If self-administering, ensure you receive proper training from your doctor or nurse on the correct injection technique.
5. Always check the solution for discoloration or particulate matter before use; do not use if observed.
Active Ingredient: Pegfilgrastim-cbqv.
Inactive Ingredients: Acetate, Polysorbate 20, Sodium, Water for injection.
Pack Size: 1 prefilled syringe.
Strength: 6 mg/0.6 mL.
Form: Solution for injection.
Manufacturer: Coherus BioSciences.
Legal Status: Prescription Only Medicine.
Benefits of Use
Fulphila helps to stimulate the production of white blood cells, specifically neutrophils, which are crucial for fighting infections.
It significantly reduces the risk of febrile neutropenia, a severe complication of chemotherapy.
By preventing infections, Fulphila allows patients to continue their chemotherapy treatments with fewer interruptions.
It provides a convenient, single-dose option per chemotherapy cycle.
How to Use
1. Fulphila is administered as a subcutaneous injection once per chemotherapy cycle.
2. The injection should be given at least 14 days before and 24 hours after a dose of myelosuppressive chemotherapy.
3. A healthcare professional will typically administer Fulphila.
4. If self-administering, ensure you receive proper training from your doctor or nurse on the correct injection technique.
5. Always check the solution for discoloration or particulate matter before use; do not use if observed.
Caution & Warnings
- Consult your healthcare provider before using Fulphila, especially if you have a history of sickle cell disease, kidney problems, or allergic reactions to pegfilgrastim or filgrastim products.
- Inform your doctor about all medications you are currently taking, including over-the-counter drugs, supplements, and herbal products.
- Seek immediate medical attention if you experience signs of an allergic reaction such as rash, itching, swelling of the face/tongue/throat, severe dizziness, or trouble breathing.
- Report any signs of an enlarged spleen or splenic rupture (e.g., pain in the upper left abdomen or shoulder tip) to your doctor immediately.
- This product may cause serious side effects, including acute respiratory distress syndrome (ARDS), glomerulonephritis, and severe allergic reactions.
- Store Fulphila in the refrigerator at 2°C to 8°C (36°F to 46°F) and protect from light. Do not freeze.
- Do not shake the syringe.
Ingredients
Active Ingredient: Pegfilgrastim-cbqv.
Inactive Ingredients: Acetate, Polysorbate 20, Sodium, Water for injection.
Product Details
Pack Size: 1 prefilled syringe.
Strength: 6 mg/0.6 mL.
Form: Solution for injection.
Manufacturer: Coherus BioSciences.
Legal Status: Prescription Only Medicine.
| Gtin | 0912211454 |
|---|---|
| Recommended Sale Price | 1886.1 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | PEGFILGRASTIM |
| SFDA Reg. No | 0912211454 |
| IBC | 0912211454 |
| Drug Type | Prescription |
| Scientific Name | Pegfilgrastim-cbqv |
| Strength | 6 mg |
| Strength Unit | mg |
| Form | Solution for injection |
| Admin Route | Subcutaneous |
| Size | 0.6 |
| Size Unit | mL |
| Package Types | Prefilled Syringe |
| Package Size | 1 prefilled syringe |
| shelfLife | 30 months |
| Storage conditions | Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze. |
| Refrigerator Storage | Yes |
Products you might like
